

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> Application of)	
)	Group Art Unit 1632
BURCOGLU)	
)	Examiner: Shin Lin Chen
Serial No. TBA)	
)	Atty. Docket No. 2939.00003
Filed: Herewith)	

For: **METHOD OF TREATING HIV INFECTION AND RELATED SECONDARY
INFECTIONS THEREOF**

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with Applicants' duty of disclosure, the following information is submitted for consideration by the United States Patent and Trademark Office in connection with the above-captioned application. The information is identified on the attached PTO 1449 form.


This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior U.S. patent application serial no. 09/754,066 (filed January 5, 2001). The references identified on the attached PTO 1449 form were submitted to and/or cited by the Office in a prior application and, therefore, copies are not required to be provided in this application. (See 37 C.F.R. § 1.98(d)). Applicants do not waive any right to take appropriate action to establish patentability over the listed documents should they be applied as references against the claims of the present application.

It is respectfully requested that the Examiner fully consider each of the documents, initial the enclosed Form PTO-1449 in the appropriate place to indicate that the document has been considered, and return a copy of the initialed form to the undersigned in accordance with MPEP Section 609.

Applicants believe that no fee is necessary pursuant to 37 C.F.R. § 1.97(b). However, if a fee is due, the Office is authorized to charge any such fee to Deposit Account No. 19-0733.

Date: Feb 2, 2004

Respectfully submitted,

By: 
Dale H. Hoschen
Registration No. 19,090

Banner & Witcoff, Ltd.
1001 G Street, N.W., Eleventh Floor
Washington, D.C. 20001-4597
(202) 824-3000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	TBA
Filing Date	Herewith
First Named Inventor	Arsinur Bircoglu
Group Art Unit	1633
Examiner Name	Shin-Lin Chen
Attorney Docket Number	2939.00003

[illegible][illegible]

**Examiner
Signature**

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	TBA
				Filing Date	TBA
				First Named Inventor	Arsinur Burcoqlu
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	002939.00003

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Mastrangelo et al., Seminars in Oncology, Vol. 23(1), p. 4-21., 2/96	
		Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 12/95	
		Franzpeter Bracht and Karsten Schorr, Biochemical and Biophysical Research Communications, Vol. 200(2) 933-937, 4/94	
		Bracht, et al., "Isolation and Identification of Aptamers from Defibrotide that Act as Thrombin Antagonists <i>in Vitro</i> ," Biochem. & Biophys Res. Comm., 200(2):933-937 (1994)	
		Harrison's PRINCIPLES OF INTERNAL MEDICINE, 10 th edition, Petersdorf et al. Eds., McGraw Hill	
		Horn et al., <i>Plant Physiol</i> , 1990, 93:1492-1496	
		Leonetti et al., <i>Bioconjugate Chem.</i> , 1990, 1:149-153	
		Notka and Pollard, 1992, <i>Aids Research and Human Retroviruses</i> 8(7):1225-1261	
		Ross, 1992, <i>Current Biology</i> , 2(10):517-519	
		Sarin et al., <i>Proc. Natl Acad. Sci. U.S.A.</i> , 1988, 85:7448-7451	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.